Menu Search
Equities

Aptevo Therapeutics Inc

AP8:DEU

Aptevo Therapeutics Inc

Actions
  • Price (EUR)0.414
  • Today's Change0.00 / 0.00%
  • Shares traded75.51k
  • 1 Year change-94.47%
  • Beta--
Data delayed at least 15 minutes, as of Jul 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

  • Revenue in USD (TTM)0.00
  • Net income in USD-25.25m
  • Incorporated2016
  • Employees40.00
  • Location
    Aptevo Therapeutics Inc2401 4th Ave Ste 1050SEATTLE 98121-3460United StatesUSA
  • Phone+1 (206) 838-0500
  • Fax+1 (206) 838-0503
  • Websitehttp://aptevotherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.